# Director, DMPK at Denali Therapeutics

- Company: Denali Therapeutics
- What the company does: Denali Therapeutics brings the power of biotherapeutics to the whole body, including the brain. We discover, develop and deliver medicines for people living with serious diseases. Backed by GV.
- Company website: https://www.denalitherapeutics.com
- Type: Startups
- Level: Principal and up
- Location: South San Francisco
- Work setup: On-site
- Posted: 2026-09-02
- Apply by: 2026-10-17
- Apply: https://dnli.wd1.myworkdayjobs.com/en-US/Development/job/South-San-Francisco/Director--DMPK_R-1655
- Page: https://www.1752.vc/careers/jobs/denali-therapeutics-director-dmpk/

## About the role

Lead and manage a group within the Nonclinical Safety Assessment and DMPK organization, providing strategic, project-focused vision and oversight to advance drug candidates from Discovery through CTA/IND-enabling studies into early clinical development ultimately supporting BLA submission. Deliver on Project Team objectives by contributing scientific expertise in pharmacokinetics, drug disposition, biodistribution, and translational pharmacology/pharmacodynamics.

## What they're looking for

- Typically requires a PhD in Pharmacokinetics, Pharmaceutical Sciences, Pharmacology/Toxicology, Engineering, or a related field
- Typically requires 10+ years of relevant experience, including 8+ years of people management, mentorship, and coaching experience
- Established expertise in biotherapeutic drug disposition and pharmacokinetics, with a track record identifying clinical candidates and advancing molecules through CTA/IND milestones to first-in-human trials
- Proven ability to evaluate drug properties impacting PK, investigate PK/PD relationships, and apply relevant bioanalytical methods (ligand binding assays, mass spectrometry, or other methodologies)
- Demonstrated success leading and/or serving on cross-functional Project Teams, contributing to data-driven decision-making and drug development strategy
- This compensation and benefits information is based on Denali’s good faith estimate as of the date of publication and may be modified in the future